Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Florida - College of Medicine/ div of Cardiovascular Medicine
Gainesville, Florida, United States
Memorial Regional Hospital
Hollywood, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Minneapolis Heart Institute at Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
The Christ Hospital
Cincinnati, Ohio, United States
Start Date
October 29, 2020
Primary Completion Date
September 28, 2022
Completion Date
September 28, 2022
Last Updated
October 17, 2023
34
ACTUAL participants
CLBS16
BIOLOGICAL
Placebo
BIOLOGICAL
Lead Sponsor
Lisata Therapeutics, Inc.
NCT07093528
NCT06795035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions